Malignant Hyperthermia by Smith, Alec
Otterbein University 
Digital Commons @ Otterbein 




Otterbein University, smith56@otterbein.edu 
Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn 
 Part of the Nursing Commons 
Recommended Citation 
Smith, Alec, "Malignant Hyperthermia" (2020). Nursing Student Class Projects (Formerly MSN). 439. 
https://digitalcommons.otterbein.edu/stu_msn/439 
This Project is brought to you for free and open access by the Student Research & Creative Work at Digital 
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an 
authorized administrator of Digital Commons @ Otterbein. For more information, please contact 
digitalcommons07@otterbein.edu. 
Malignant Hyperthermia
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Introduction: 
Malignant 
Hyperthermia
• Malignant	Hyperthermia	
(MH)	is	a	life-threatening	
disease	process	that	can	
be	fatal	if	untreated.	
• MH	is	an	autosomal	
dominant	
pharmacogenetic	
disorder	(Smith	et	al.,	
2018).
• This	disorder	is	often	
precipitated	by	the	use	of
volatile	anesthetics	and	
depolarizing	muscle	
relaxants.
• Although	MH	is	fairly	
uncommon,	it	accounts	
nearly	1%	of	all	
anesthesia	related	deaths	
(Bamaga et	al.,	2016).
Why Malignant 
Hyperthermia?
• MH	can	be	caused	by	
medications	frequently	
administered	by	the	
anesthesia	team.
• Anesthesia	providers	
and	nurses	are	tasked	
with	early	detection,	
treatment,	and	clinical	
monitoring	for	patients	
who	develop	MH.
• Vigilance	along	with	
proper	education	and	
training	on	this	disease	
process	can	help	reduce	
fatalities	associated	
with	MH	(Smith	et	al.,	
2018).
Pathophysiological Processes
Signs & Symptoms
• MH	can	present	at	any	point	during	an	
anesthesia	case.	MH	can	develop	shortly	
after	giving	the	triggering	medications	and	
can	be	seen	up	to	one	hour	after	the	
discontinuation	of	these	medications	
(Rosenberg	et	al.,	2015).
• Although,	MH	can	be	seen	during	an	
individuals	first	exposure	to	anesthesia,	it	
can	often	take	up	to	three	exposures	before	
MH	is	triggered	(Rosenberg	et	al.,	2015).
• One	of	the	early	signs	of	MH	is	the	
unexplained	increase	in	end-tidal	CO2	
(ETCO2)	with	increased	ventilation	(Smith	
et	al.,	2018).
• Additional	symptoms	of	MH	include	
tachycardia,	dysrhythmias,	skeletal	muscle	
rigidity,	rapid	rise	in	core	body	
temperature,	and	rhabdomyolysis	(Smith	et	
al.,	2018).
• As	MH	progresses,	later	symptoms	include	
metabolic	and	respiratory	acidosis,	
hyperkalemia,	myoglobinuria,	and	
increased	levels	of	creatine	kinase	(CK)	
(Smith	et	al.,	2018).
• If	the	symptoms	of	MH	are	untreated	for	
long	enough,	other	pathologies	such	as	
disseminated	intravascular	coagulation	
and/or	acute	renal	failure	may	occur	(Smith	
et	al.,	2018).
• Another	symptom	of	MH	that	is	specific	to	
children	is	masseter	muscle	rigidity	
(Rosenberg	et	al.,	2015).
Underlying 
Pathophysiology
• MH	is	a	disease	process	that	can	be	
potentiated	by	potent	inhaled	
anesthetic	gases	such	as	sevoflurane,	
isoflurane,	desflurane,	halothane.	MH	
can	also	be	caused	by	non-
depolarizing	muscle	relaxants	like	
succinylcholine	(Abdulrahman,	
2020).
• In	MH,	a	defect	or	mutation	exists	in	
the	calcium	channel	termed	the	
ryanodine	receptor	(RyR1).	This	
channel	is	responsible	for	the	
regulation	and	release	of	calcium	
from	the	sarcoplasmic	reticulum	(SR)	
into	the	cell	Rosenberg	et	al.,	2015).
• By	introducing	these	anesthetic	
agents	into	individuals	with	this	
defect,	an	uncontrolled	release	of	
calcium	from	the	SR	into	the	cell	can	
result.	This	then	causes	a	
hypermetabolic	state	with	sustained	
muscle	contraction,	rigidity,	and	
hyperthermia.	(Dagestad &	Hermann,	
2017).
• This	hypermetabolic	state	results	in	
excessive	consumption	and	depletion	
of	adenosine-tri	phosphate	(ATP)	
which	then	leads	to	the	failure	of	
membrane	integrity	and	the	release	
of	CK	and	potassium.	(Rosenberg	et	
al.,	2015).
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Significance of Physiology
• MH	is	a	rare	genetic	disorder	and	because	of	this	it	is	not	often	
diagnosed	until	symptoms	develop.
• The	“gold	standard”	test	for	the	diagnosis	of	MH	is	the	in	vitro	
contracture	test	(IVCT).	This	test	is	based	the	contracture	of	muscle	
fibers	when	introduced	to	caffeine	of	halothane.	An	individual	is	
considered	susceptible	to	MH	when	muscle	fiber	contracture	results	
from	both	caffeine	and	halothane.	However,	IVCT	is	expensive,	
requires	surgical	intervention,	and	is	only	done	at	specialized	testing	
centers	(Rosenberg	et	al.,	2015).
• Another	option	to	determine	susceptibility	to	MH	is	genetic	testing.	
While	this	can	provide	useful	data,	it	may	also	have	ramifications	for	
the	future	health	of	individuals	and	their	immediate	family	
members.	Genetic	testing	can	also	be	disadvantageous	regarding	the	
ability	of	a	individuals	to	gain	employment	or	access	health	and/or	
life	insurance,	therefore,	the	previously	mentioned	IVCT	is	preferred	
(Rosenberg	et	al.,	2015).
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Treatment
• Rapid	treatment	of	MH	is	essential	in	preventing	adverse	outcomes	
pertaining	to	MH.	It	is	suggested	that	treatment	be	initiated	within	
3-7	minutes	from	the	time	of	onset	(Dagestad &	Hermann,	2017).
• After	the	discontinuation	of	provoking	anesthetic	agents,	dantrolene	
can	be	administered	to	treat	MH.	Dantrolene	is	a	direct-acting	
skeletal	muscle	relaxant	that	interferes	with	calcium	release	to	help	
stop	skeletal	muscle	contraction	(Dagestad &	Hermann,	2017).	
• Dantrolene	is	administered	intravenously	with	a	maximum	dose	of	
10mg/kg.	A	maintenance	dose	then	recommended	48	hours	from	
the	time	of	the	last	MH	related	symptom	(Dagestad &	Hermann,	
2017).
• Other	treatments	for	MH	are	symptomatic	and	include	ensuring	the	
patient	is	normothermic.
• In	addition	to	the	initial	treatments	listed	above,	other	therapies	
such	as	extracorporeal	membrane	oxygenation	(ECMO)	and	
continuous	renal-replacement	therapy	(CRRT)	may	be	beneficial	in	
more	severe	cases	(Huh	et	al.,	2017).
Implications for 
Nursing Care
• A	large	part	of	the	prevention	of	MH	
comes	in	the	preoperative	assessment.	
It	is	vital	that	all	members	of	the	
healthcare	team	ensure	a	thorough	
assessment	is	completed	(Rosenberg	et	
al.,	2015).
• In	order	to	optimize	outcomes	from	
patients	diagnosed	with	MH	it	is	
imperative	that	nursing	staff	in	the	OR	
and	PACU	be	diligent	in	monitoring	the	
patient’s	condition.
• Nursing	must	be	knowledgeable	in	the	
presentation	of	MH	so	subtle	changes	in	
patient	condition	can	be	identified	and	
reported.	This	includes	familiarity	with	
monitoring	devices	such	as	ETCO2,	
pulse	oximetry	saturation	(SpO2),	and	
core	temperature	monitoring	systems.	
Nursing	must	not	only	know	how	to	use	
this	equipment,	but	know	what	values	
are	expected	in	different	situations	(Xu	
et	al.,	2019).	
• Knowledge	of	treatment	as	well	as		how	
to	rapidly	access	different	treatments	
such	as	dantrolene	is	essential	for	
nursing	staff.
• Specific	for	anesthesia	providers	– a	
knowledge	of	alternative	treatment	and	
medications	for	MH	susceptible	patients	
is	imperative.	
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Conclusions
• MH	is	a	rare	genetic	disorder	
and	a	complications	of	
anesthesia	with	an	incidence	
of	only	1:10,000	cases.	
However,	once	MH	begins	its	
rapid	progression	can	cause	
multiple	organ	failure	leading	
to	death	(Pan	et	al.,	2016).
• MH	is	a	serious	complication	
that	healthcare	providers	
must	have	a	thorough	
understanding	of.	
• Hyperthermia	in	MH	can	
measured with	a	core	
temperature	increase	of	1-2	
degrees	Celsius	every	5	
minutes	(Rosenberg	et	al.,	
2015).
• Rapid	detection	and	treatment	
is	the	key	to	decreasing	
mortality	related	to	MH.	
• Children,	younger	adults,	and	
males	are	at	an	increased	risk	
for	MH	(Rosenberg	et	al.,	
2015).
• Dantrolene	works	by	
decreasing	RyR1	channel	
activity	and	is	imperative	in	
treating	MH	(Rosenberg	et	al.,	
2015).
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